C Difficile Infection

Findings showed colonization with toxigenic C. difficile was associated with a greater risk of CDI during hospitalization than cross-transmission.

Survey results showed patients with a history of live biotherapeutic product therapy preferred rectally administered treatment while patients who had not received live biotherapeutic product therapy would be willing to consider it.

Patients with CDI and COVID-19 faced a higher risk of mortality and had higher CCI scores, a longer length of stay, and greater total hospital costs than patients infected with COVID-19 but not CDI.

Investigators called attention to low patient-reported levels of clinician recommendation for colorectal cancer screening during wellness visits, noting the prevalence was lowest among those without insurance and without a usual source of care.

Patients with CDI treated with oral metronidazole experienced significantly more first-line drug changes compared to those on fidaxomicin, although there were no significant differences observed in the global or clinical cure rate between the two treatments.

Vedolizumab, anti-TNF, and 5-ASA treatments were not linked to an increased risk of CDI, but investigators noted other baseline variables were significantly associated with CDI risk in patients with IBD.

Results from the study found a high risk of CDI associated with clindamycin and low risk associated with doxycycline and minocycline, also highlighting variation in CDI risk within and between classes of antibiotics.

Qazi reviews an analysis of an EHR-assisted smoking cessation module that could improve conversations between specialists and patients.

While discussing a review of noninvasive options, the gastroenterologist addresses the growing interest in non-colonoscopy screening and surveillance methods.

A Mayo Clinic study shows FMT may provide benefit for patients experiencing recurrent infections during their C difficile treatment.

Qazi reviews the selective JAK1 inhibitor's benefit for patients who previously failed TNF inhibitor regimen.

A protein targeted by some marketed lipid-lowering agents may increase risk of developing irritable bowel disease.

The first known dose-effect relationship study between colorectal neoplasia and smoking in patients with IBD strengthens the importance of achieving cessation.

New cohort analysis data provide more context into what factors influence the benefit of FMT in patients with recurrent CDI.

A study from China suggests calcium and magnesium malnutrition is associated with Crohn's disease inflammation and activity.

New data from the CONFIRM trial show the noninvasive FIT testing method is increasing in preference over colonoscopy by about 20% annually.

A cross-sectional analysis from China suggests approximately 1 in 10 individuals suffer from incontinence, though not all are seeking adequate care or specialist consultation.

Early-stage data support KAN-101, a liver-targeting drug that's vying to become the first treatment approved to treat celiac disease.

The reported C difficile healthcare-acquired infections rates per 10,000 patient days did not significantly change. The rates were 8.07 in the 6-month preintervention period and 8.77 in the intervention period for facilities A and B combined.

Experts provide practice pearls for educating patients on and using FMTs for the management of CDI.

The area under the concentration-time curve (AUC) for vancomycin at discharge was the only modifiable factor found that was independently associated with patient safety outcomes.

The most frequent mutations found in the analyzed genomes was fluoroquinolone-associated mutations such as gyrA and there were 24 different sequence types were identified in the 130 isolates.

Kiwifruit supplementation did not have an impact on stool frequency or consistency, but magnesium oxide supplementation did result in improved stool frequency.

The median exposure of vedolizumab was 1.93 years and lower incidence rates were found for infliximab or adalimumab.

The interrupted time-series resulted in an increase in C. difficile infection incidences during the pre-pandemic period from 0.00 to 3.36 infections per 10,000 bed days during the COVID-19 pandemic.